A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic lymphocytic leukaem...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Br J Haematol
Main Authors: Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.
Formáid: Artigo
Teanga:Inglês
Foilsithe: John Wiley and Sons Inc. 2017
Ábhair:
Haematological Malignancy
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412890/
https://ncbi.nlm.nih.gov/pubmed/28220479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14534
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla